CTW0415 is an experimental drug from the piperidine family, which acts as a selective positive allosteric modulator of the 5-HT2C receptor, with higher potency than older drugs such as VA012. Structure-activity relationship studies showed that small variations to chain length and side chain substitution could lead to preferential binding for either 5-HT2C or the related 5-HT2A receptor, which subsequently led to the discovery of the related 5-HT2A selective positive allosteric modulator CTW0404.[1][2][3]
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C15H22N2O3 |
| Molar mass | 278.352 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
References
edit- ↑ Wold EA, Garcia EJ, Wild CT, Miszkiel JM, Soto CA, Chen J, et al. (July 2020). "Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT2C Receptor-Positive Allosteric Modulators with Enhanced Drug-like Properties". Journal of Medicinal Chemistry. 63 (14): 7529–7544. doi:10.1021/acs.jmedchem.9b01953. PMC 8434884. PMID 32567857.
- ↑ Zamora JC, Merritt CR, Bolinger AA, Fox RG, Wild CT, Wold EA, et al. (2024). "Serendipitous Discovery of Novel 5-HT2AR Positive Allosteric Modulators (PAMs) Derived From 5-HT2CR PAM Scaffolds". The Journal of Pharmacology and Experimental Therapeutics. 389: 87. doi:10.1124/jpet.087.985400.
- ↑ WO 2023/023287, Zhou J, Cunningham KA, Bolinger AA, Anastasio NC, "Novel heterocyclic compounds as serotonin (5-ht) 5-ht2a and 5-ht2c receptor positive allosteric modulators.", published 22 February 2024, assigned to The Board of Regents of the University of Texas System